Literature DB >> 11768242

Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats.

P H Goldspink1, R D McKinney, V A Kimball, D L Geenen, P M Buttrick.   

Abstract

Recently, the calcium-calmodulin-dependent calcineurin pathway has been defined as a central pathway for the induction of cardiac hypertrophy. The purpose of this study was to determine if cardiac hypertrophy in animals chronically treated with angiotensin II (AngII), could be prevented by blocking this pathway with cyclosporin A (CsA). Female Wistar rats were treated with AngII by subcutaneous infusion and injected twice a day with CsA (25 mg/kg) for 7 days. In the AngII treated group there was a 30% increase in the heart/body weight ratio (p < 0.05 vs. control). The increase in heart weight was blocked with CsA. Substantial increases in ANF and betaMHC gene expression were detected in the AngII treated animals, which were either attenuated or blocked with CsA treatment. Thus, this study demonstrates that CsA does prevent the development of cardiac hypertrophy in AngII treated rats, suggesting that the calcium-calmodulin-dependent calcineurin pathway is associated with angiotensin II induced hypertrophy in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768242     DOI: 10.1023/a:1012789819926

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  25 in total

1.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.

Authors:  T Taigen; L J De Windt; H W Lim; J D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy.

Authors:  M Shimoyama; D Hayashi; E Takimoto; Y Zou; T Oka; H Uozumi; S Kudoh; F Shibasaki; Y Yazaki; R Nagai; I Komuro
Journal:  Circulation       Date:  1999-12-14       Impact factor: 29.690

3.  Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy.

Authors:  H W Lim; L J De Windt; L Steinberg; T Taigen; S A Witt; T R Kimball; J D Molkentin
Journal:  Circulation       Date:  2000-05-23       Impact factor: 29.690

4.  Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats.

Authors:  W Zhang; R C Kowal; F Rusnak; R A Sikkink; E N Olson; R G Victor
Journal:  Circ Res       Date:  1999-04-02       Impact factor: 17.367

5.  Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure.

Authors:  T Meguro; C Hong; K Asai; G Takagi; T A McKinsey; E N Olson; S F Vatner
Journal:  Circ Res       Date:  1999-04-02       Impact factor: 17.367

Review 6.  Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes.

Authors:  P Lijnen; V Petrov
Journal:  J Mol Cell Cardiol       Date:  1999-05       Impact factor: 5.000

Review 7.  Signaling pathways in cardiac myocyte hypertrophy.

Authors:  M A Hefti; B A Harder; H M Eppenberger; M C Schaub
Journal:  J Mol Cell Cardiol       Date:  1997-11       Impact factor: 5.000

8.  Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro.

Authors:  H Aoki; M Richmond; S Izumo; J Sadoshima
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

9.  Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition.

Authors:  H W Lim; L J De Windt; J Mante; T R Kimball; S A Witt; M A Sussman; J D Molkentin
Journal:  J Mol Cell Cardiol       Date:  2000-04       Impact factor: 5.000

10.  Post-transcriptional regulation of glyceraldehyde-3-phosphate-dehydrogenase gene expression in rat tissues.

Authors:  M Piechaczyk; J M Blanchard; L Marty; C Dani; F Panabieres; S El Sabouty; P Fort; P Jeanteur
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

View more
  11 in total

Review 1.  CaMKII in the cardiovascular system: sensing redox states.

Authors:  Jeffrey R Erickson; B Julie He; Isabella M Grumbach; Mark E Anderson
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

2.  Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth.

Authors:  Benjamin J Wilkins; Leon J De Windt; Orlando F Bueno; Julian C Braz; Betty J Glascock; Thomas F Kimball; Jeffery D Molkentin
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

3.  Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II.

Authors:  Joan Li; Jianchun Wang; Fraser D Russell; Peter Molenaar
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

Review 4.  Calcineurin and cardiac hypertrophy: where have we been? Where are we going?

Authors:  Benjamin J Wilkins; Jeffery D Molkentin
Journal:  J Physiol       Date:  2002-05-15       Impact factor: 5.182

5.  Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse renin gene, TGR(mREN2)27.

Authors:  H Diedrichs; C Mei; K F Frank; B Boelck; R H G Schwinger
Journal:  J Mol Med (Berl)       Date:  2004-08-20       Impact factor: 4.599

6.  Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?

Authors:  Xiang Wang; Ana-Maria Bosonea; Jeffrey Odenbach; Carlos Fernandez-Patron
Journal:  Curr Hypertens Rev       Date:  2012-08-01

Review 7.  Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney.

Authors:  Virginie Descazeaud; Elodie Mestre; Pierre Marquet; Marie Essig
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

8.  Compensatory renal hypertrophy following uninephrectomy is calcineurin-independent.

Authors:  Clintoria R Williams; Brandi M Wynne; Makeeva Walker; Robert S Hoover; Jennifer L Gooch
Journal:  J Cell Mol Med       Date:  2014-10-07       Impact factor: 5.310

9.  Calcineurin A-β is required for hypertrophy but not matrix expansion in the diabetic kidney.

Authors:  Ramesh N Reddy; Taylor L Knotts; Brian R Roberts; Jeffery D Molkentin; S Russ Price; Jennifer L Gooch
Journal:  J Cell Mol Med       Date:  2011-02       Impact factor: 5.310

10.  E2/ER β inhibit ISO-induced cardiac cellular hypertrophy by suppressing Ca2+-calcineurin signaling.

Authors:  Cheng-Yen Tsai; Wei-Wen Kuo; Marthandam Asokan Shibu; Yueh-Min Lin; Chien-Nam Liu; Yi-Hui Chen; Cecilia-Hsuan Day; Chia-Yao Shen; Vijaya Padma Viswanadha; Chih-Yang Huang
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.